Now FDA Approved
Menu
Publications and Presentations
Publications
Clément, K., et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes & Endocrinology. Online first (2020). https://doi.org/10.1016/S2213-8587(20)30364-8
Haws, R., et al.Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes, Obesity and Metabolism, 10.1111/dom.14133 (2020). Advance online publication. https://doi.org/10.1111/dom.14133
Clément, K., et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat. Med. 24, 551–555 (2018). https://doi.org/10.1038/s41591-018-0015-9
Kühnen, P., et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. New England Journal of Medicine; 375:240-6. DOI: 10.1056/NEJMoa1512693(2016). https://www.nejm.org/doi/10.1056/NEJMoa1512693
Garfield, AS. et al. Role of central melanocortin pathways in energy homeostasis. Trends in Endocrinology and Metabolism: TEM, 203-215. DOI: 10.1016/j.tem.2009.02.002 (2009).https://doi.org/10.1016/j.tem.2009.02.002
To request a copy of an article, email medinfo@rhythmtx.com.
Presentations
ENDO 2021 – Annual Meeting of the Endocrine Society
“Effects of Setmelanotide in Patients With POMC, PCSK1, or LEPR Heterozygous Deficiency Obesity in a Phase 2 Study,”
an oral presentation by Sadaf Farooqi, M.D., Ph.D., professor at the Wellcome-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre
March 20, 2021 oral presentation slides
“A Phase 3 Trial in Participants with Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide,” a poster presentation by Robert Haws, M.D., Clinical Research Center at the Marshfield Clinic Research Institute
March 20, 2021 poster presentation
“Timing of Onset of Adverse Events with Setmelanotide, an MC4R Agonist, in Patients with Severe Obesity Due to LEPR or POMC Deficiency,” a poster presentation by Peter Kühnen, MD, Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin in Berlin
March 20, 2021 poster presentation
The Obesity Society’s ObesityWeek® 2020
“A Randomized Trial of a Once-Weekly Formulation of Setmelanotide in Individuals with Obesity,” an oral presentation by Gregory Gordon, MD, JD, Vice President, Clinical at Rhythm
Nov. 5, 2020 oral presentation slides
“Long-term Weight and Hunger Reduction With Setmelanotide in Individuals With POMC Deficiency Obesity,” a poster presentation by Karine Clément, MD, PhD, and Professor of Nutrition at Pitié-Salpêtrière Hospital and Sorbonne Université in Paris
Nov. 3, 2020 poster presentation
“Suicidality and Depression in Individuals With Genetic Obesity Treated With Setmelanotide,” a poster presentation by Peter Kühnen, MD, Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin in Berlin
Nov. 3, 2020 poster presentation
The Obesity Society’s ObesityWeek® 2019
“Efficacy and Safety of the MC4R Agonist Setmelanotide in POMC Deficiency Obesity: A Phase 3 Trial,” presented by Peter Kühnen, M.D., Institute for Experimental Pediatric Endocrinology, Charité Universitäts medizin Berlin, Germany
Nov. 4 oral presentation slides
Nov. 7 poster presentation
“Efficacy and Safety of the MC4R Agonist Setmelanotide in LEPR Deficiency Obesity: A Phase 3 Trial,” oral presentation by Erica Van Den Akker, M.D., Ph.D., Erasmus MC-Sophia Children’s Hospital University in Rotterdam, Netherlands
Nov. 4 oral presentation slides
Nov. 7 poster presentation